Ulrik is a co-founder and Chief Scientific Officer of Merrimack Pharmaceuticals. For the past seven years, he has been part of the executive team where he is responsible for research and early development. Ulrik was instrumental in building the company’s Network Biology platform and oncology pipeline. Prior to joining Merrimack, he was a post-doctoral fellow at Massachusetts Institute of Technology, where he researched the interface among biology, engineering and computational biology. Ulrik received his M.S. and Ph.D. degrees from the University of Copenhagen in molecular biology and trained at the University of California, San Francisco. Ulrik has also undertaken extensive executive business education, including education at Harvard Business School (PLD graduate).